Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra Inc. (NYSE: PEN) delivers innovative medical technologies transforming vascular intervention worldwide. This news hub provides investors and healthcare professionals with essential updates on the company's thrombectomy systems, regulatory milestones, and market strategies.
Access real-time press releases covering product approvals, clinical trial results, and financial performance. Our curated news collection includes analysis of Penumbra's neurovascular devices, partnership announcements, and global expansion initiatives.
Key updates feature developments in computer-assisted vacuum thrombectomy (CAVT) technology, peripheral vascular solutions, and quality improvement initiatives. Stay informed about Penumbra's progress in addressing ischemic stroke, pulmonary embolism, and other critical vascular conditions.
Bookmark this page for verified updates on Penumbra's operational achievements and industry leadership. Check regularly for insights into how the company's medical devices continue shaping modern interventional therapies across 100+ countries.
Penumbra has scheduled its Q2 2024 earnings release and conference call for July 30, 2024, at 4:30 PM ET. The company will issue a press release with financial results after the market closes on that day. Investors can join the earnings call by dialing (888) 596-4144 with the conference ID 5872954 or access the webcast via Penumbra's website under the 'Investors' tab. The webcast will remain available for at least two weeks post-call.
Penumbra announced its participation in the Truist Securities MedTech Conference on June 18, 2024. The presentation will be at 10:05am ET/7:05am PT. Investors can access the webcast through the company’s website under the 'Events and Presentations' section. The webcast will be available for two weeks post-event.
Penumbra announced that its management team will present at the William Blair Growth Stock Conference on June 6, 2024, at 12:20pm ET/9:20am PT.
The event will be webcast live and accessible through the company's website under the 'Investors' tab, where it will remain available for two weeks after the presentation.
Penumbra, Inc. reported strong financial results for the first quarter of 2024, with revenue reaching $278.7 million, a 15.4% increase over the previous year. The company's U.S. thrombectomy revenue saw a significant growth of 35.2%. The non-GAAP income from operations was $19.3 million, and adjusted EBITDA was $37.6 million with a margin of 13.5%. Penumbra's total revenue growth and U.S. thrombectomy revenue guidance for the full year 2024 are 16-20% and 27-30%, respectively. The company expects continued growth in revenue and gross margin expansion for the year.
Penumbra, Inc. (NYSE: PEN) will be presenting at the RBC Capital Markets Global Healthcare Conference on May 15, 2024. The webcast of the presentation will be available on the company's website for two weeks after the event.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
